Is Compounded Semaglutide Being Discontinued? The 2026 FDA Update (and What to Do Next)
Published: · Last reviewed:
By The RX Index Editorial Team — independent guidance for choosing your GLP-1 path.
Last verified: June 2026. Regulatory dates and prices change fast; we re-check the linked sources monthly.
Is compounded semaglutide being discontinued? For the routine, mass-produced copies sold during the shortage — mostly yes. The FDA declared the semaglutide shortage over in February 2025, and its grace period for pharmacies to stop making those copies ended in April and May 2025. But it is not fully banned. Narrow, patient-specific compounding can still be legal, and some FDA-approved semaglutide is now a fraction of the old $1,300-style price.
Here's the part the scary headline left out: the thing that ends for most people isn't treatment — it's the loophole. And the door that's closing came with a surprise on the other side that actually works in your favor. We'll get to it. First, the straight answer, the exact dates, and your next move — without the panic, and without anyone steering you toward the wrong thing.
This page is for you if:
- • Your compounded semaglutide refill got delayed, canceled, or switched.
- • You saw a headline saying it's “banned” and your stomach dropped.
- • A telehealth company told you it's “still legal” and you don't know whether to believe it.
- • You want to compare real options without being pushed onto a $1,000+ drug or a sketchy website.
Not the page for you if:
- • You're having a medical emergency — call your doctor or 911.
- • You want dosing instructions or to switch without a clinician.
- • You want a page that treats compounded and FDA-approved drugs as the same. They're not.
The 30-second answer
| Your question | Straight answer | What to do next |
|---|---|---|
| Is compounded semaglutide being discontinued? | The routine mass-produced copies are largely gone. The legal reason for making them ended when the shortage ended. | Find out why your specific prescription is still being filled. |
| Is all compounding banned? | No. Patient-specific compounding can still be legal in narrow cases. | Ask your prescriber for the documented medical reason. |
| Should I stop taking it today? | No — do not stop, double up, or switch based on an article. | Message your prescriber before your next dose. |
| What's the safest next step? | Compare FDA-approved, insurance, and cash-pay paths — separately from compounded. | Use the matching tool below. |
Get your compounded semaglutide transition plan.
Tell us your state, your insurance, why you were on compounded semaglutide, and whether you want FDA-approved or are open to a personalized option. In about a minute, we'll show you the treatment path most worth checking next, with current prices, plus the exact questions to ask your provider.
Get my transition plan with Find My GLP-1 Path →Free · ~60 seconds · On your phone? A button will follow you down the page from here.
What we actually verified for this page
We don't ask you to take our word for it. Every regulatory and price claim here traces to a primary source, with links at the bottom of the page. Here's what we checked:
- • The FDA determined the semaglutide injection shortage was resolved on February 21, 2025. (FDA)
- • The FDA's enforcement-discretion (grace) period ended April 22, 2025 for 503A pharmacies and physicians, and May 22, 2025 for 503B outsourcing facilities. (FDA)
- • On April 30, 2026, the FDA proposed leaving semaglutide, tirzepatide, and liraglutide off the 503B “bulks list” — a proposal, not a final ban. (FDA; Federal Register 91 FR 23431, docket 2026-08552)
- • The public comment window ran through June 29–30, 2026 (FDA announcement: June 29; Federal Register: June 30).
- • On March 3, 2026, the FDA announced 30 warning letters to telehealth companies for marketing claims implying compounded products were “the same” as FDA-approved drugs. (FDA)
- • The FDA says compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before they're sold. (FDA)
- • Current FDA-approved self-pay prices were checked at NovoCare and LillyDirect, and Ro's program and insurance terms against Ro's own pages and our June 2026 Ro review. (NovoCare; LillyDirect; Ro; The RX Index)
Is compounded semaglutide being discontinued in 2026?
Compounded semaglutide means a version mixed by a pharmacy rather than manufactured and FDA-approved. During the shortage, the FDA used what's called enforcement discretion — it chose not to act against pharmacies making these copies — so patients could still get treatment while the brand-name drugs were hard to find. That was always temporary. It was tied to the shortage, not to the drug being cheap or popular.
So “discontinued” is the word patients use, but it's not quite right. A more accurate way to say it: the shortage exception closed, and the routine copies that lived inside it are going away. The FDA didn't say “no one can ever receive compounded semaglutide.” It said the broad, copy-style version no longer has a legal home now that the brand-name drug is available again.
The dates that actually matter
The real timeline, with sources. Bookmark this.
| Date | What happened | Why it matters to you |
|---|---|---|
| 2022 | Semaglutide and tirzepatide added to the FDA shortage list | This is the door that let pharmacies start making copies. |
| Oct 2024 | FDA found the tirzepatide shortage resolved | Tirzepatide copies started winding down first. |
| Feb 21, 2025 | FDA marked the semaglutide shortage resolved | This is the moment the clock started for compounded semaglutide. |
| Mar 2025 | A federal judge declined to block the FDA | The compounding industry sued; the deadlines held. |
| Apr 22, 2025 | FDA's enforcement-discretion period ended for 503A (state-licensed) pharmacies and physicians | The cheap copies began disappearing from most telehealth menus. |
| May 22, 2025 | FDA's enforcement-discretion period ended for 503B (large outsourcing) facilities | Bulk, large-scale copy production ended. |
| Mar 3, 2026 | FDA announced 30 warning letters to telehealth firms over “same as the brand” claims | Enforcement got real, not just policy on paper. |
| Apr 30, 2026 | FDA proposed leaving semaglutide, tirzepatide, and liraglutide off the 503B bulks list | Would close the last large-scale compounding door. |
| Jun 29–30, 2026 | Public comment window closes (FDA announcement: June 29; Federal Register: June 30) | This is the live news driving your search right now. |
What “discontinued” really means for you
Most people typing this question are really asking: “Will I still be able to get the cheap semaglutide I've been getting online?”
The honest answer: not the way you did during the shortage. A pharmacy can stop offering it. A telehealth platform can stop prescribing it. And the FDA has made clear the broad, routine version is no longer legal now that the shortage is over. If your provider is still filling it, there should be a specific, documented reason — and you have every right to ask what it is. (We'll hand you the exact questions in a minute.)
Why is this happening? The shortage rule, in plain English
Compounded semaglutide access changed because the FDA's shortage status changed. During an official shortage, the FDA relaxes its stance on copying an approved drug so patients can still get treatment. Once the shortage ends, that flexibility goes away — and a copy of an available, FDA-approved drug is generally no longer allowed.
Think of it this way. FDA-approved drugs go through years of review for safety, how well they work, and how they're made. Compounded drugs skip that review — which is fine for genuine custom needs, but it means they were never meant to be a permanent, cheaper stand-in for a blockbuster drug. The shortage created a temporary opening. That opening is now closing.
503A vs. 503B — what those numbers mean
| Term | What it means | Why you care |
|---|---|---|
| 503A pharmacy | A state-licensed pharmacy that compounds for one specific patient with a prescription. | This is how many patient-specific telehealth prescriptions are framed — but verify yours. |
| 503B outsourcing facility | A larger, FDA-registered facility that can make compounded drugs in bigger batches. | This powered a lot of the cheap, mass supply during the shortage. |
| “Essentially a copy” | The FDA's term for a compounded drug that closely mirrors an available approved product. | This is the exact thing that's no longer allowed once the shortage ends. |
| “Clinical difference” | A prescriber-documented reason a patient genuinely needs the compounded version. | This is the narrow exception that keeps some compounding legal. |
Why adding B12 doesn't automatically fix it
A lot of compounded semaglutide comes mixed with vitamin B12 or other add-ins, and you may have been told that makes it “different” enough to keep going. Be careful here. The FDA's point is narrow but firm: adding B12 or another ingredient does not automatically make the product different enough to avoid the “essentially a copy” problem. The documented, patient-specific medical reason is what counts — not the add-in by itself.
Is compounded semaglutide still legal in 2026?
Compounded semaglutide reality check — verified June 2026
Find yourself in the left column. Sources: FDA compounding policy and safety statements; Federal Register 91 FR 23431.
| If this is your situation | What the FDA rules mean | What to ask before you refill | Safer next path to compare |
|---|---|---|---|
| “I get routine compounded semaglutide because it was cheaper.” | The cheap, copy-style version is the thing that's gone. The shortage ended Feb 21, 2025; grace periods ended spring 2025. | “What documented, patient-specific reason supports compounding this for me now?” | Compare FDA-approved cash-pay options (below). |
| “My telehealth provider says it's still legal.” | That can be true in narrow cases — but broad marketing doesn't prove your prescription qualifies. | “Is this based on my individual medical need, or mainly price and convenience?” | Ask for the documented reason; if none, compare FDA-approved. |
| “Mine has B12 (or another add-in).” | An add-in doesn't automatically make it legal; it can still be “essentially a copy.” | “What medical reason requires the added ingredient, and is it in my chart?” | If not documented, compare FDA-approved options. |
| “The site calls it 'generic Wegovy' or 'the same as Ozempic.'” | Major red flag. The FDA warns sellers not to claim compounded products are generic or the same as approved drugs. | “Where's the FDA-approved label? Who's the licensed prescriber and pharmacy?” | Treat it as a warning; use FDA's BeSafeRx and choose a legitimate path. |
| “It's labeled semaglutide sodium or semaglutide acetate.” | The FDA says these salt forms are different active ingredients than approved semaglutide, with no known lawful basis for compounding. | “Is this the base form of semaglutide, not a salt form? Can you document it?” | Avoid salt-form offers unless a clinician clearly verifies it. |
| “It's a 'research use only' product I buy online.” | The FDA warns against products labeled 'research use only' — they may be counterfeit or wrongly dosed. | “Is this prescribed by a licensed clinician and filled by a licensed pharmacy?” | If no — don't use it. |
| “I just want an FDA-approved option.” | Available now, and cheaper than you think. Wegovy is approved for weight management; Ozempic for type 2 diabetes. | “Which FDA-approved product fits me, and will insurance help?” | See the price table and provider paths below. |
What a legitimate personalized compounded prescription looks like
Legal compounding didn't vanish — it just got narrow and specific. A defensible compounded prescription in 2026 generally has all of these:
- A real, licensed prescriber who evaluated you
- A documented medical reason an FDA-approved product can't meet
- A named, state-licensed pharmacy you can verify
- The base form of semaglutide (not a salt form)
- Proper cold-chain shipping
An identical product sold to thousands of customers with no individual reason is exactly what the FDA is now acting against.
Is compounded tirzepatide being discontinued too?
Same direction. The FDA found the tirzepatide shortage resolved back in 2024, and tirzepatide is not currently back on the shortage list. The April 2026 proposal targets it right alongside semaglutide. If you're on compounded tirzepatide, treat your timeline the same way: confirm the documented reason, and have a plan B ready. FDA-approved Zepbound is the brand version, and its self-pay price has dropped sharply — more on that below.
How to spot an unsafe or illegal “still available” offer
The red-flag checklist
| Red flag | Why it matters | What to do |
|---|---|---|
| “Generic Wegovy” or “same as Ozempic” | The FDA warns sellers not to market compounded drugs as generic or identical to approved ones — and sent 30 telehealth firms warning letters over this in March 2026. | Treat it as a serious trust warning. |
| “Clinically proven, same results” | This claim isn't allowed for non-approved compounded products. | Look for an FDA-approved label — or leave. |
| Semaglutide sodium or acetate | The FDA says these salt forms are different active ingredients with no known lawful basis for compounding. | Avoid unless a clinician can clearly verify it's the base form. |
| “Research use only” / “not for human consumption” | The FDA warns these aren't for self-treatment and may be counterfeit. | Do not buy. Full stop. |
| No prescription, or no licensed prescriber | The FDA says to get compounded drugs only with a prescription, from a licensed pharmacy. | Don't use it. |
| Product arrives warm, with no cold packs | Injectable GLP-1s need refrigeration; a warm shipment is a quality risk. | Contact the prescriber/pharmacy before using. |
| Vague or hidden pharmacy source | The FDA has found fake labels naming pharmacies that didn't make the product — or don't exist. | Ask for the pharmacy's name and license, and verify it. |
The “too cheap” test
A low price isn't automatically a scam. But a low price with no transparency is a problem. A legitimate program can tell you, without dodging: who the licensed prescriber is, which pharmacy dispenses it, whether the medication is FDA-approved or compounded, what's included in the monthly price, how to cancel, and what happens if you're not approved. If a site won't answer those, that's your answer.
Two free tools worth knowing: the FDA's BeSafeRx campaign helps you check whether an online pharmacy is legitimate, and you can report a bad product or a suspected reaction to FDA MedWatch.
Before you refill anywhere, run your next option through our matching tool — it only routes you to legitimate, clinician-directed paths, so you're not guessing whether a site is safe.
Check your next option safely →What to do right now if your refill is delayed, canceled, or switched
Don't panic-stop, and don't chase the first “still available” ad. Save your current prescription details, message your prescriber before your next planned dose, ask whether there's a documented reason your medication is still being compounded, and compare FDA-approved options before your supply runs out. When the deadlines hit in 2025, many patients reported getting mixed messages — or no message at all — from their providers, so being the one who asks the specific questions puts you back in control.
Your 48-hour action plan
| Step | Do this | Why |
|---|---|---|
| 1 | Photograph your current prescription label and note the pharmacy name. | You need the exact product and source to compare anything. |
| 2 | Message your prescriber before your next dose. | Stopping or switching should be clinician-guided, not self-directed. |
| 3 | Ask if your prescription has a documented, patient-specific reason. | This tells you whether compounding can legally continue for you. |
| 4 | Ask about FDA-approved alternatives and prices. | You likely have more affordable options than you assume. |
| 5 | Check insurance and cash-pay paths side by side. | The cheapest path depends on your plan, state, and medication. |
| 6 | Avoid no-prescription, salt-form, or "research use" offers. | The FDA flags these as real safety risks. |
Copy-paste these questions to your provider
You don't have to be a regulatory expert to advocate for yourself. Send this:
Before I refill, can you tell me:
- Why is a compounded product medically appropriate for me now that the shortage has ended?
- Is that reason documented in my chart?
- Which licensed pharmacy dispenses this medication?
- Is it the base form of semaglutide — not semaglutide sodium or acetate?
- What happens if the pharmacy stops making it?
- Which FDA-approved options should I compare?
- How should I handle a missed dose, side effects, or switching?
Note: If your provider says your prescription is “grandfathered,” that's not a recognized exemption on its own — ask for the documented patient-specific reason and the dispensing pharmacy.
When to get medical help
As of July 31, 2025, the FDA said it had received about 1,150 reports of adverse events tied to compounded semaglutide and tirzepatide, many involving dosing errors. Get urgent care for:
- Severe or lasting vomiting
- Signs of dehydration
- Severe belly pain
- Fainting or confusion
When in doubt, call your clinician. This page is not a dosing guide.
Your legitimate options now — and what they actually cost in 2026
Current FDA-approved self-pay prices — verified June 2026
| Option | Self-pay price | Retail list price (context) | Notes |
|---|---|---|---|
| Wegovy injection (semaglutide, via NovoCare) | $199/mo first 2 fills (through Jun 30, 2026); then $349/mo | ~$1,350/mo | Approved for weight management. With commercial insurance + savings, as little as $25/mo. |
| Wegovy oral pill (via NovoCare) | $149/mo (1.5 mg & 4 mg; 4 mg offer through Aug 31, 2026, then $199/mo) | ~$1,350/mo | First FDA-approved oral semaglutide for weight management. |
| Ozempic (semaglutide, via NovoCare) | $199/mo first 2 fills (through Jun 30, 2026); then $349/mo (0.25/0.5/1 mg) or $499/mo (2 mg) | ~$998/mo | Approved for type 2 diabetes — not the weight-loss indication. |
| Zepbound vials (tirzepatide, via LillyDirect) | $299–$449/mo (dose-dependent, when you refill on time) | ~$1,086/mo | Approved for weight management. Miss the 45-day refill window and prices jump. |
| Foundayo (orforglipron, oral, via Ro/LillyDirect) | Starts ~$149/mo; higher doses cost more | — | A newer FDA-approved oral GLP-1. Confirm current price and eligibility. |
Prices change frequently. Confirm at NovoCare, LillyDirect, Ro, or your provider before relying on any number above.
Path 1 — FDA-approved with insurance help (where most people should start)
If you have commercial insurance, this is usually your cheapest and most stable path — and it's the most relevant answer for someone losing compounded access. Ro is the provider we point most people to here, because it's built around FDA-approved medication plus an insurance concierge — a team that checks your plan, fights prior authorizations, and submits the paperwork for you.
Ro's insurance coverage applies to the Wegovy pen, Zepbound autoinjector pen, and Ozempic (Foundayo and the Wegovy pill are cash-pay). If your plan covers your medication, you pay only your plan's copay, billed separately from the membership. Ro Body membership is $39 the first month, then as low as $74/month with the annual plan paid upfront (otherwise $149/month). In our June 2026 review, Ro holds about 3.8/5 on Trustpilot across more than 3,000 reviews, with insurance support cited again and again as the reason people chose it.
Sponsored affiliate link · Opens in a new tab · Doctor evaluation + insurance concierge
Path 2 — Provider choice (Sesame Care)
If you'd rather choose your own clinician from a marketplace and want more control over who you see, Sesame Care is a solid alternative. Its Success by Sesame weight-loss program starts at $99/month and doesn't include the medication; providers set their own visit prices, and a Sesame provider can send your Wegovy or Zepbound prescription to NovoCare or LillyDirect at the same self-pay cash prices. Confirm the current medication price at checkout.
See GLP-1 options on Sesame → (sponsored affiliate link, opens in a new tab)Partner link · $99/mo program + medication billed separately
Path 3 — Manufacturer-direct (NovoCare / LillyDirect)
If you already have a prescription and want the lowest flat cash price without a membership, going directly to NovoCare (for Wegovy or Ozempic) or LillyDirect (for Zepbound or Foundayo) is the simplest path. No membership fee, no extra layer — you pay the manufacturer's self-pay price directly. This is also available through TrumpRx.gov, which links out to these same platforms.
Not an affiliate link · Novo Nordisk's own platform
Not an affiliate link · Eli Lilly's own platform
Path 4 — Legitimate patient-specific compounding (narrow cases only)
If your prescriber has documented a genuine medical reason an FDA-approved product can't meet your need — a commercially unavailable dose, an allergy to an ingredient in the approved formulation, or another specific clinical basis — a 503A pharmacy may still legally compound for you.
Run any program claiming to offer this through the checklist above. The minimum bar for a defensible compounded prescription:
- A real, licensed prescriber who evaluated you
- A documented, specific clinical reason in your chart
- The base form of semaglutide (not sodium or acetate salt forms)
- A named, state-licensed 503A pharmacy you can independently verify
- Proper cold-chain shipping and storage instructions
Medicare, Medicaid, and TRICARE note
Beginning July 1, 2026, the CMS Medicare GLP-1 Bridge covers eligible Part D members for a $50/month copay (through December 31, 2027) on Foundayo, Wegovy (injection and tablets), and the Zepbound KwikPen — prior authorization required. If you have Medicare, check our Medicare GLP-1 Bridge guide before deciding. Medicaid and TRICARE have their own formulary and eligibility rules — check your plan before assuming cash-pay is your only move.
How we'd route you — the matching table
| Your situation | What we'd suggest | What to avoid |
|---|---|---|
| I used compounded only because it was cheaper | Compare FDA-approved cash-pay and insurance paths before chasing another compound. | Assuming every cheap ad is legitimate. |
| I have a documented medical need for a compound | Ask your prescriber to document it and verify the pharmacy and source. | Any program that can't explain the medical basis. |
| I want FDA-approved medication | Compare Wegovy, Zepbound, Foundayo, and insurance-first options. | Treating compounded and approved drugs as equal. |
| I am injection-averse | Ask about FDA-approved oral options (Wegovy pill, Foundayo). | Assuming “oral compounded” is automatically safer. |
| I saw a “research use only” product | Don't use it for self-treatment. | Anything without a prescription and a licensed pharmacy. |
| I have Medicare, Medicaid, or TRICARE | Check your plan and the Medicare GLP-1 Bridge — coverage rules are different. | Assuming self-pay or savings-card prices apply to you. |
How we'd route you, simply: If you're uncertain or deciding between paths, start with the matching tool. If you're insured and want help getting covered, Ro is the strongest fit. If you want provider choice, look at Sesame. If you want one flat cash price, go manufacturer-direct. And if a clinician has documented a real compounding need, evaluate a legitimate program against the checklist above. No single provider is “the winner” — the winner is the path that fits your situation.
Does one of those rows sound like yours?
Answer a few questions and get a personalized GLP-1 treatment-path match based on your state, insurance, budget, and whether you want FDA-approved or are open to a compounded option.
Use Find My GLP-1 Path →What we verified, what we didn't, and how we reach conclusions
We separate three kinds of claims on purpose: regulatory facts (sourced to the FDA, CMS, and the Federal Register), commercial facts like pricing (sourced to provider and manufacturer pages on a dated basis), and editorial judgments (clearly labeled as our opinion, built on those verified facts). That separation is what makes this page trustworthy on a topic where a wrong “fact” can cost you money or your health.
The RX Index Score evaluates GLP-1 treatment paths on five pillars, in this order: clinical legitimacy, care quality, transparency, access, and cost. Our recommendations come from those pillars applied to verified facts — never from payout alone.
What we did not verify, so you know the limits:
- Your personal medical eligibility — only your clinician can assess that.
- Every provider's availability in every state.
- Every insurance plan's formulary and prior-authorization rules.
- Every pharmacy used by every telehealth provider.
- Dosing, switching, or any individual medical advice — we don't give it.
Frequently asked questions
Is compounded semaglutide banned?
No, it is not a blanket ban. The routine, mass-produced copies are gone now that the shortage is over, but patient-specific compounding can still be legal when a prescriber documents a medical need an FDA-approved product cannot meet. The April 2026 FDA action is a proposal, not a final rule.
Why is compounded semaglutide being discontinued?
Because the FDA declared the semaglutide injection shortage resolved on February 21, 2025, which ended the temporary enforcement discretion that allowed broad compounding. The grace periods ended in April and May 2025, and a copy of an available FDA-approved drug is generally no longer allowed.
Can I still get compounded semaglutide from a 503A pharmacy?
Possibly -- but not just because it is cheaper or easier. A 503A pharmacy compounds for an individual patient, and the prescriber needs a real, documented medical reason when an FDA-approved version exists. Ask what that reason is for you.
Can 503B outsourcing facilities still make compounded semaglutide?
The rules are much tighter after the shortage ended, and the FDA's April 2026 proposal would close the remaining large-scale path by leaving semaglutide off the 503B bulks list. That proposal was open for public comment through late June 2026.
Is compounded semaglutide the same as Wegovy or Ozempic?
No. Compounded semaglutide is not an FDA-approved finished drug and is not reviewed by the FDA for safety, effectiveness, or quality. Wegovy and Ozempic are FDA-approved products made by Novo Nordisk.
Are semaglutide sodium and semaglutide acetate safe?
The FDA says these salt forms are different active ingredients than the semaglutide in approved drugs, and it is not aware of any lawful basis for using them in compounding. If a product lists a salt form, treat it as a red flag and ask your clinician.
What if I cannot afford Wegovy?
FDA-approved Wegovy runs about $349 per month at standard self-pay through NovoCare, down from a roughly $1,350 list price, and oral options start near $149. With commercial insurance plus a concierge, your copay can be far lower. Compare all of those before assuming a questionable compound is your only choice.
Does Medicare cover GLP-1s for weight loss now?
Beginning July 1, 2026, the CMS Medicare GLP-1 Bridge gives eligible Medicare Part D members certain GLP-1 medications for a $50 monthly copay through December 31, 2027, for weight-management use. Eligible drugs include Foundayo, Wegovy injection and tablets, and the Zepbound KwikPen, and prior authorization is required.
Should I buy semaglutide labeled 'research use only'?
No. The FDA warns against using GLP-1 products labeled 'research use only' or 'not for human consumption' for self-treatment -- they may be counterfeit, contaminated, or wrongly dosed.
Should I switch from compounded to Wegovy, Foundayo, Zepbound, or Ozempic?
That is a clinician's call, not a shopping decision. Bring your current label, dose, last dose date, side effects, and goals to your prescriber, then compare FDA-approved options by your indication, insurance, and budget.
Will compounded semaglutide come back?
The broad, shortage-based compounded market would most likely require the shortage to return or a major policy shift -- and the current direction is the opposite, with courts letting the deadlines stand and the 2026 proposal tightening things further. Narrow, patient-specific compounding can still exist when a prescriber documents a medical need an FDA-approved product cannot meet.
Still not sure which GLP-1 program is right for you?
You've got the facts, the dates, and your options. The last step is matching them to your state, insurance, and budget — and that's the one part an article can't do for you. Take our free 60-second matching quiz. You'll get a personalized GLP-1 treatment-path match, with source-verified pricing, based on whether you want FDA-approved medication or are open to a legitimate compounded option.
Use The RX Index's Find My GLP-1 Path tool →Free · No email to start · Source-verified pricing
Related guides:
- Best Telehealth GLP-1 Providers (2026): Every Option Compared
- GLP-1 Cost Without Insurance: Every Cash-Pay Option Compared
- Ro GLP-1 Review (2026): Pricing, Coverage & Real Ratings
- Medicare GLP-1 Bridge: the $50 Copay, Eligibility & Drugs Covered
- TrumpRx Zepbound: Price by Dose & the 45-Day Catch
- Is TrumpRx Legit? The Honest Answer for GLP-1 Shoppers
- Find My GLP-1 Path — free personalized match tool
Primary sources (verified June 2026):
- FDA — FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (Feb 21, 2025 shortage resolution; Apr 22 / May 22, 2025 enforcement-discretion end dates)
- FDA — FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List (April 30, 2026)
- Federal Register — List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B, 91 FR 23431, docket 2026-08552
- FDA — FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s (March 3, 2026)
- FDA — FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (salt forms, research-use-only, counterfeit, BeSafeRx)
- FDA — FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs
- CMS — Medicare GLP-1 Bridge (July 1, 2026–Dec 31, 2027; $50 copay; eligible drugs)
- NovoCare Pharmacy — Wegovy and Ozempic self-pay pricing
- LillyDirect — Zepbound and Foundayo pricing
- Ro — Weight Loss Program pricing and insurance (ro.co)
- The RX Index — Ro GLP-1 review (Trustpilot/pricing, verified June 2026): /guides/ro-glp1-reviews/
By The RX Index Editorial Team · Independent guidance for choosing your GLP-1 path · Published June 2026 · Last verified: June 2026.
Your situation changes the answer
Find My GLP-1 Path
The right GLP-1 provider isn't the same for everyone. It depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred route (injection or oral), and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a personalized provider match with source-verified pricing before you choose.
- What it asks: your state, insurance situation, medication preference, budget, and support needs
- What you get: a personalized shortlist of GLP-1 providers matched to your situation, with verified pricing and the right questions to ask
- Cost: free · about 60 seconds · no signup